The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Capitol Hill

Bhattacharya provides calm answers to anxious questions at confirmation hearing

Trump nominee for NIH director calls for transparency, audits of indirect costs

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Amid the flood zone of today’s Washington, the confirmation hearing for Jayanta (Jay) Bhattacharya’s nomination as director of NIH was remarkably calm.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Jacquelyn Cobb
Associate Editor
Table of Contents

YOU MAY BE INTERESTED IN

Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure

The day before health economist Jay Bhattacharya stepped into his new role as NIH director, he sent a document to his employees outlining his top five priorities for the department, which included “reproducibility” and “transparency,” two themes he discussed at his confirmation hearings (The Cancer Letter, March 7, 2025).
By Claire Marie Porter, Paul Goldberg and Jacquelyn Cobb
Clinical Roundup

Fatty acids promote immune suppression and therapy resistance in triple negative breast cancer, Baylor Medicine study finds

A study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.
Byline
Jacquelyn Cobb
Associate Editor
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account